Administration of autologous bone marrow derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life

Sharma, Anita; Gokulchandran, Nandini; Chopra, Guneet; Kulkarni, Pooja; Lohia, Mamta; Badhe, Prerna; V., C. Jacob

doi:10.3727/096368911x633798

Cited by 17 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delivery of BM nucleated cells to achieve neuroprotective and neurorestorative effects is an attractive goal [39], since BM provides several kind of cells, as previously noted, with regenerative potential besides CD34+ stem cells [28,30,31]. Other advantages of this kind of source for stem cells include fewer days of G-CSF stimulation, no need for central catheter placement or apheresis procedures, and therefore low complication rate in this kind of very sick patient [31].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore a theoretical framework exists suggesting that cells injected directly into the subarachnoid space can be a safe approach [29][30][31]. There are several published studies regarding the safety of subarachnoid cell placement by intrathecal (IT) injection, with various cell types, methods of procurement, doses administered and acceptable adverse rates [30,31].…”

Section: Introductionmentioning

confidence: 99%

“…Current clinical trials are based on two main administration strategies: the systemic [24] and local approaches [25][26][27][28] Stem cell delivery into the spinal cord and the placement into the frontal motor cortex have been described and reported as safe methods [23,26,27] After introducing stem cells into the subarachnoid space of the spinal cord, these cells can be transported by cerebrospinal fluid (CSF) and delivered more accurately to the injured areas than is expected by using the systemic route [25]. Furthermore a theoretical framework exists suggesting that cells injected directly into the subarachnoid space can be a safe approach [29][30][31]. There are several published studies regarding the safety of subarachnoid cell placement by intrathecal (IT) injection, with various cell types, methods of procurement, doses administered and acceptable adverse rates [30,31].…”

Section: Introductionmentioning

confidence: 99%

“…Several types of progenitor cells can be obtained from human marrow, including MSCs, endothelial and very small embryonic stem cells [30,31]. Nowadays, mobilized peripheral blood is the more attractive source of cells for allogeneic and autologous stem cell transplantation, however, G-CSF stimulated BM has several advantages in the setting of cell therapy, higher concentration of different cells can be obtained in a lower volume from the BM, and it has been reported that MSCs among others, increase their numbers in situ after G-CSF administration without mobilization to the peripheral blood [31].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Intrathecal delivery of bone marrow stem cells in ALS: A preliminary report

Martínez¹,

Gómez‐Almaguer²,

Jaime‐Pérez³

et al. 2017

Transplant Open

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intrathecal delivery of bone marrow stem cells in ALS: A preliminary report

Martínez¹,

Gómez‐Almaguer²,

Jaime‐Pérez³

et al. 2017

Transplant Open

View full text Add to dashboard Cite

show abstract

“…It has gained popularity in the management of various neurological disorders such as ALS, stroke, Alzheimer, spinal cord injury, and TBI [15][16][17][18][19]. Preclinical studies [9][10][11] have used various types of stem cells and different routes of administration in the treatment of TBI.…”

Section: Discussionmentioning

confidence: 99%

Effect of cell transplantation in a chronic case of traumatic brain injury

Sharma¹,

Sane²,

Kulkarni³

et al. 2017

Transplant Open

Self Cite

View full text Add to dashboard Cite

Traumatic Brain Injury (TBI) is defined as an injury to the brain parenchyma resulting in neurological deficit following a trauma. Cell transplantation has evolved as a novel treatment modality in the management of TBI. Autologous Bone Marrow Mononuclear Cells (BMMNCs) have shown beneficial effects in the functional recovery of neurological deficits. We present a case of a 15 year old female who suffered from a TBI due to a road traffic accident, 7 years ago. She underwent two doses of intrathecal transplantation of autologous BMMNCs for chronic TBI. No severe adverse events were noted. She showed improvements in her speech, cognitive abilities, memory, higher function and fine motor skills. PET CT scan was used as a monitoring tool to evaluate the effect of cellular transplantation at a cellular level. On comparing the PET CT scan brain performed 6 months after the intervention with the previous scan, increased metabolic activity in various areas of the brain was observed. These changes also correlated to the functional improvements observed in the patient. Hence, stem cell transplantation may have a promising future as a therapeutic intervention in chronic TBI.

show abstract

Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial

Sharifzadeh

Ghasemi

Afshari

et al. 2020

Asia-Pacific Psychiatry

View full text Add to dashboard Cite

Introduction: This study aimed to determine the safety and efficacy of treatment with autologous bone marrow mesenchymal stem cell (BMMSCs) compared with the routine treatment in children with autism spectrum disorder (ASD).Methods: In this ethically approved randomized controlled trial, 32 ASD children aged 5-15 years were randomly assigned to receive either autologous BMMSC plus rehabilitation therapy and risperidone (intervention group) or rehabilitation therapy and risperidone (control group). Autologous BMMSCs were intrathecally injected in the intervention group twice in 4 weeks. Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale-second edition (GARS-II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention.Results: Overall, 32 patients in two groups of intervention (n = 14) and control (n = 18) completed the study, of which 27 (84.4%) were male. Mean age was 9.50 ± 2.14 years. The improvements in CARS total score, GARS-II autism index, and CGI global improvement showed no significant differences between the groups over 12 months. However, the main effect for time*group interaction was significant regarding the CGI-severity of illness, showing a significantly more pronounced improvement in the intervention group (F = 6.719; P = .002).Discussion: Intrathecal injection of autologous BMMSCs seems to be safe and feasible, but has limited clinical efficacy in treatment of children with ASD.augmentation therapy, autism spectrum disorder, autologous bone marrow stem cell, mesenchymal stem cell | INTRODUCTIONAutism spectrum disorder (ASD), characterized by difficult social communication, restricted interests and repetitive behaviors in early childhood, which cannot be justified by other medical or neurological condition (Volden, 2017), affects about 1% of the general population (Baio et al., 2018;Must et al., 2017). Despite its increasing prevalence, there are still no effective treatments for ASD based on its etiology and pathophysiology. The development of targeted therapies for ASD, however, has been hindered by the fact that the mechanisms

show abstract

Administration of autologous bone marrow derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life

Cited by 17 publications

References 0 publications

Intrathecal delivery of bone marrow stem cells in ALS: A preliminary report

Intrathecal delivery of bone marrow stem cells in ALS: A preliminary report

Effect of cell transplantation in a chronic case of traumatic brain injury

Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial

Contact Info

Product

Resources

About